French pharmaceutical giant Sanofi (SASY.PA) announced on Tuesday its collaboration with Formation Bio and OpenAI, an artificial intelligence company, to enhance its drug research efforts using AI.
In a statement, Sanofi mentioned that Formation Bio will provide additional engineering resources, while the partnership with OpenAI will grant access to proprietary data to develop AI models for its biopharma initiatives.
Major pharmaceutical companies are increasingly leveraging artificial intelligence to identify clinical trial participants more efficiently and reduce the number of subjects needed for drug testing, potentially accelerating drug development and saving millions of dollars.
 announced on Tuesday its collaboration with Formation Bio and OpenAI, an artificial intelligence company, to enhance its drug research efforts using AI.){kind=link}